RE:Antibody-drug conjugates (ADCs) company CCO departsADCs encounter major obstacles including, low blood residency time, low penetration capacity to tumor microenvironment, low payload potency, immunogenicity, unusual off-target toxicity, drug resistance, and the lack of stable linkage in blood circulation.
That said (ADCs) are an emerging therapeutic modality for targeted cancer treatment that represent the amalgamation of chemotherapy and immunotherapy which work to deliver a chemo/immunotherapies payload at the targeted cancer cells.
So ADCs are just a targeted delivery modality for chemotherapy agents which inherently retain all of the side effects that chemotherapy agents traditionally exhibit.